A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER) - Austin, Cary D.; Gonzalez Edick, Melissa; Ferrando, Ronald E.; Solon, Margaret; Baca, Miriam; Mesh, Kathryn; Bradding, Peter; Gauvreau, Gail M.; Sumino, Kaharu; FitzGerald, J. Mark; Israel, Elliot; Bjermer, Lief; et al. (Clinical and experimental allergy, 2020)
Keywords: Adolescent; Adult; Aged; Airway Remodeling - drug effects; Allergology; Anti-Asthmatic Agents - adverse effects; Anti-Asthmatic Agents - pharmacokinetics; Anti-Asthmatic Agents - therapeutic use; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Asthma; Asthma - drug therapy; Asthma - immunology; Asthma - physiopathology; Biomarkers; Bronchoscopy; Clinical trials; Collagen (type I); Double-Blind Method; Eosinophils - drug effects; Eosinophils - immunology; Eosinophils - metabolism; Female; Fibrosis; Gene expression; Human health and pathology; Humans; Immunology; Immunotherapy; Inflammation; Interleukin 13; Interleukin-13 - antagonists & inhibitors; Leukocytes (eosinophilic); Life Sciences; Lung - drug effects; Lung - immunology; Lung - physiopathology; Male; Middle Aged; Monoclonal antibodies; Nitric oxide; Original; ORIGINAL ARTICLES; Patients; Pharmacodynamics; Pulmonology and respiratory tract; Respiratory function; Respiratory tract; Respiratory tract diseases; Signal Transduction; Time Factors; Treatment Outcome; Young Adult